COVID-19患者使用高流量鼻导管与非侵入通气的多中心观察研究
该研究在中国4家医院回顾性纳入2020年1月至3月的COVID-19患者,23例以HFNC、13例以NIV作为一线治疗。结果显示两组HFNC+NIV持续时间(中位7.1 vs 7.3天)、插管率(17% vs 15%)和死亡率(4% vs 8%)均无显著差异。HFNC组10例失败后改用NIV补救,NIV组1例(8%)因不耐受改用HFNC补救。全体患者中C反应蛋白与插管独立相关(OR=1.04,95%CI 1.01-1.07)。参与HFNC和NIV管理的医护人员无院内感染发生。
要点
- COVID-19危重患者以HFNC或NIV一线治疗,插管率17% vs 15%、死亡率4% vs 8%,均无显著差异。
- HFNC一线治疗23例中10例失败改用NIV补救;NIV一线治疗13例中1例(8%)因不耐受改用HFNC。
- 全体患者中C反应蛋白与插管独立相关(OR=1.04,95%CI 1.01-1.07)。
- 从启动HFNC或NIV至插管时间为8.4天(IQR 4.4-18.5),未插管者至终止时间为7.1天(IQR 3.9-10.3)。
- 参与HFNC和NIV管理的医护人员无院内感染发生。
适用人群与场景
- 中国4家医院2020年1月至3月回顾性纳入的COVID-19患者,分别以HFNC(23例)或NIV(13例)作为一线治疗。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 第一步:以HFNC作为一线治疗(23例),失败后改用NIV作为补救治疗(10例)。
- 第一步:以NIV作为一线治疗(13例),因不耐受改用HFNC作为补救治疗(1例,8%)。
- 原文未提及具体药物剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- HFNC一线治疗失败需改用NIV补救(23例中10例)。
- NIV不耐受需改用HFNC补救(13例中1例,8%)。
- C反应蛋白升高与插管独立相关(OR=1.04,95%CI 1.01-1.07)。
研究设计与关键结果
- 干预与对照:HFNC vs NIV作为一线治疗。
- 主要终点:HFNC+NIV持续时间中位7.1天(IQR 3.5-12.2)vs 7.3天(IQR 5.3-10.0),无显著差异。
- 插管率:HFNC组17% vs NIV组15%,无显著差异;死亡率:HFNC组4% vs NIV组8%,无显著差异。
- 全体患者插管率17%(6例);从启动HFNC或NIV至插管时间8.4天(IQR 4.4-18.5)。
- C反应蛋白与插管独立相关(OR=1.04,95%CI 1.01-1.07)。
- 参与HFNC和NIV管理的医护人员无院内感染。
证据类型、等级与局限
- 证据类型:多中心回顾性观察研究。
- 局限性:原文未述局限性。
对床旁实践的改变
- 在COVID-19危重患者中,HFNC或NIV作为一线治疗时,两组HFNC+NIV持续时间、插管率和死亡率无显著差异。
- HFNC一线治疗失败后可改用NIV补救,NIV不耐受后可改用HFNC补救。
- C反应蛋白与插管独立相关,OR=1.04(95%CI 1.01-1.07)。
- 参与HFNC和NIV管理的医护人员无院内感染发生。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The use of high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) in patients with COVID-19 is debated.
METHODS: This study was performed in four hospitals of China from January to March 2020. We retrospectively enrolled 23 and 13 COVID-19 patients who used HFNC and NIV as first-line therapy, respectively.
RESULTS: Among the 23 patients who used HFNC as first-line therapy, 10 experienced HFNC failure and used NIV as rescue therapy. Among the 13 patients who used NIV as first-line therapy, one (8%) used HFNC as rescue therapy due to NIV intolerance. The duration of HFNC + NIV (median 7.1, IQR: 3.5-12.2 vs. 7.3, IQR: 5.3-10.0 days), intubation rate (17% vs. 15%) and mortality (4% vs. 8%) did not differ between patients who used HFNC and NIV as first-line therapy. In total cohorts, 6 (17%) patients received intubation. Time from initiation of HFNC or NIV to intubation was 8.4 days (IQR: 4.4-18.5). And the time from initiation of HFNC or NIV to termination in patients without intubation was 7.1 days (IQR: 3.9-10.3). Among all the patients, C-reactive protein was independently associated with intubation (OR = 1.04, 95% CI: 1.01-1.07). In addition, no medical staff got nosocomial infection who participated in HFNC and NIV management.
CONCLUSIONS: In critically ill patients with COVID-19 who used HFNC and NIV as first-line therapy, the duration of HFNC + NIV, intubation rate and mortality did not differ between two groups. And no medical staff got nosocomial infection during this study.
参考来源
- Duan J, Chen B, Liu X, et al. Use of high-flow nasal cannula and noninvasive ventilation in patients with COVID-19: A multicenter observational study. Am J Emerg Med. 2020. PMID: 33046296. doi:10.1016/j.ajem.2020.07.071
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。